Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118086 · ClinicalTrials.gov registry record · Phase 1
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
A Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by Remix Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT06118086: Recruiting Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by Remix Therapeutics.
NCT06118086 is a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma that is actively recruiting participants, run by Remix Therapeutics. The registered enrollment target is 100 participants, below the 122-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (18% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06118086, a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, is actively recruiting participants, sponsored by Remix Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Primary Outcome
Frequency and severity of Treatment Emergent Adverse Events (TEAEs) will be evaluated according to the NCI-CTCAE version 5.0 and number of participants with Dose Limiting Toxicities will be assessed to determine Safety and Tolerability of REM-422
Conditions Studied
Interventions
- DRUG REM-422
Study Locations (8)
Other
- Centre Antoine Lacassagne - Nice
- Institut de Cancerologie Gustave-Roussy - Villejuif
California
- University of California San Francisco Helen Diller Comprehensive Cancer Center - San Francisco
Massachusetts
- Dana Farber Cancer Research Institute - Boston
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
What NCT06118086 shows while recruiting
NCT06118086 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 122-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (18% lower).
The record links to 3 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which REM-422 is the first listed.
NCT06118086 lists 8 locations in 7 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06118086 about?
NCT06118086 is a clinical study titled "Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma". The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
What is the current status of trial NCT06118086?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-12-20. Estimated completion is 2027-06-01.
What conditions does trial NCT06118086 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT06118086?
The interventions under investigation include: REM-422 (DRUG).
Who is sponsoring clinical trial NCT06118086?
This trial is sponsored by Remix Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118086 being conducted?
This trial has 8 study locations across California, Massachusetts, Michigan, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06118086's enrollment target sits among peer trials
100 5th of 16 higher than 12 of 16 other Adenoid Cystic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenoid Cystic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
RECRUITING · Phase 1
-
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RECRUITING · Phase 1
-
A Study of XMT-1660 in Participants With Solid Tumors
RECRUITING · Phase 1
-
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI